News
Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Nordisk said Tuesday the company struck its second licensing deal since it received a poor reception from investors after presenting its long-term strategy.
More in Business
- Cat and rat droppings, flies, dead cockroaches: Why Mumbai’s century-old Kyani & Co faces FDA action Mint
- ‘I have $400,000 in equity’: I’m 80 years old. Should I move out of my house because of dangerous stairs? MarketWatch
- OpenAI DevDay live updates: Altman faces safety questions, Meta AI chief pokes fun at rival CNBC — World News
- Mideast Oil Exports Rebound Even as Prices Remain Elevated The New York Times — Business
- Soho House launches investigation after out-of-date food mislabelled in kitchen The Guardian — Business